Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Neuropediatrics|November 9, 2013
Update on pediatric opsoclonus myoclonus syndromeBarbara Hero, Gudrun Schleiermacher
Medical and Pediatric Oncology|May 24, 2003
FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastomaRuediger Spitz, Barbara Hero, Thorsten Simon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
The Lancet. Oncology|August 7, 2003
Neuroblastoma: biology and molecular and chromosomal pathologyManfred Schwab, Frank Westermann, Barbara Hero, et al.
Pediatric Blood & Cancer|April 1, 2005
Lacking immunocytological GD2 expression in neuroblastoma: report of 3 casesRoswitha Schumacher-Kuckelkorn, Barbara Hero, Karen Ernestus, et al.
Journal of Pediatric Hematology/Oncology|February 7, 2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trialThorsten Simon, Alfred Längler, Frank Berthold, et al.
Future Oncology (London, England)|June 13, 2009
Molecular characterization and classification of neuroblastomaAndré Oberthuer, Jessica Theissen, Frank Westermann, et al.
Journal of Pediatric Hematology/Oncology|December 14, 2004
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN statusThorsten Simon, Rüdiger Spitz, Andreas Faldum, et al.
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Neuropediatrics|November 9, 2013
Update on pediatric opsoclonus myoclonus syndromeBarbara Hero, Gudrun Schleiermacher
Medical and Pediatric Oncology|May 24, 2003
FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastomaRuediger Spitz, Barbara Hero, Thorsten Simon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
The Lancet. Oncology|August 7, 2003
Neuroblastoma: biology and molecular and chromosomal pathologyManfred Schwab, Frank Westermann, Barbara Hero, et al.
Pediatric Blood & Cancer|April 1, 2005
Lacking immunocytological GD2 expression in neuroblastoma: report of 3 casesRoswitha Schumacher-Kuckelkorn, Barbara Hero, Karen Ernestus, et al.
Journal of Pediatric Hematology/Oncology|February 7, 2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trialThorsten Simon, Alfred Längler, Frank Berthold, et al.
Future Oncology (London, England)|June 13, 2009
Molecular characterization and classification of neuroblastomaAndré Oberthuer, Jessica Theissen, Frank Westermann, et al.
Journal of Pediatric Hematology/Oncology|December 14, 2004
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN statusThorsten Simon, Rüdiger Spitz, Andreas Faldum, et al.
Pageof 15